RET‐rearranged non‐small‐cell lung cancer and therapeutic implications. Issue 12 (5th December 2019)

• Record Type: Journal Article
• Authors: Loh, Zoe; Mitchell, Paul; John, Thomas; Arulananda, Surein
• Is Part Of: Internal medicine journal. Volume 49:Issue 12(2019)
• Page Start: 1541
• Page End: 1545
• Publication Date: 2019-12-05
• Subjects: non‐small‐cell lung cancer -- RET rearrangement -- genomic profiling -- tyrosine kinase inhibitor -- vandetanib; Medicine -- Periodicals; 616
• DOI: 10.1111/imj.14654
• Languages: English
• ISSNs: 1444-0903

Abstract

Abstract: First‐line tyrosine kinase inhibitors are standard of care for non‐small‐cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c‐ros oncogene 1 rearrangement. Other targetable oncogenic drivers have been identified but testing for these is neither funded nor commonly performed in Australia. Using a case example, we discuss the importance of considering several other genomic aberrations in our population, such as rearrangements in the RET proto‐oncogene, which occur in 1–2% of lung adenocarcinoma. New oncogenic drivers and corresponding targeted agents are constantly being discovered; these will continue to refine the treatment of non‐small‐cell lung cancer in the era of precision medicine.